Valemetostat Therapy for Relapsed Adult T-Cell Leukemia/Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation - PubMed
6 hours ago
- #valemetostat
- #allogeneic hematopoietic stem cell transplantation
- #adult T-cell leukemia/lymphoma
- Valemetostat was evaluated as salvage therapy for relapsed adult T-cell leukemia/lymphoma (ATL) after allogeneic hematopoietic cell transplantation (allo-HCT).
- The study included 11 patients with a median age of 64 years at allo-HCT.
- The median interval between allo-HCT and valemetostat therapy was 210 days.
- 73% of patients showed a clinical response, including complete or partial responses.
- Two patients achieved molecular responses with clearance of measurable residual disease.
- Adverse events leading to discontinuation included cytomegalovirus infection, pericardial effusion, and dysgeusia.
- No patients developed graft-versus-host disease during treatment.
- Median overall survival after valemetostat therapy was 294 days.
- At last follow-up, four patients were alive without disease, four with disease, and three died due to progressive disease.
- Valemetostat shows promise as a salvage therapy for relapsed ATL post-allo-HCT.